DOCSLIB.ORG

AHFS Pharmacologic-Therapeutic Classification System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AHFS Pharmacologic-Therapeutic Classification System AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective beta-Adrenergic Blocking Agents - Afatinib 10:00 - Antineoplastic Agents - 314007 24:04.04.16 - Class II Antiarrhythmics - 387003 24:08.92 - Hypotensive Agents, Miscellaneous - 387003 Aflibercept Acesulfame 52:92 - EENT Drugs, Miscellaneous - 312025 40:24 - Salt and Sugar Substitutes - 379001 Agalsidase Beta Acetaminophen 44:00 - Enzymes - 303023 28:08.92 - Analgesics and Antipyretics, Miscellaneous - Albendazole 8:08 - Anthelmintics - 397043 28:32.92 - Antimigraine Agents, Miscellaneous - 381004 Albiglutide acetaZOLAMIDE 68:20.06 - Incretin Mimetics - 314021 52:40.12 - Carbonic Anhydrase Inhibitors - 382756 Albumin Human 24:08.24.04 - Carbonic Anhydrase Inhibitors - 382756 16:00 - Blood Derivatives - 382142 28:12.92 - Anticonvulsants, Miscellaneous - 382756 Albuterol/Levalbuterol 40:28.04 - Carbonic Anhydrase Inhibitors - 382756 12:12.08.12 - Selective beta-2-Adrenergic Agonists - Acetic Acid 40:36 - Irrigating Solutions - 308023 48:12.04.12 - Selective beta-2-Adrenergic Agonists - Acetohydroxamic Acid 40:10 - Ammonia Detoxicants - 384050 Alcaftadine Acetylcholine 52:02 - Antiallergic Agents - 311014 52:40.20 - Miotics - 382406 Alclometasone Acetylcysteine 84:06.08 - Corticosteroids - 387002 92:12 - Antidotes - 382638 Alcohol, Isopropyl © 2019, American Society of Health-System Pharmacists, Inc. Page 1 of 44 52:92 - EENT Drugs, Miscellaneous - 379002 44:00 - Enzymes - 389001 84:04.92 - Local Anti-infectives, Miscellaneous - 379003 Altretamine Aldesleukin 10:00 - Antineoplastic Agents - 308015 10:00 - Antineoplastic Agents - 392009 Aluminum Acetate 92:20 - Immunomodulatory Agents - 392009 84:12 - Astringents - 308010 Alectinib Aluminum Carbonate 10:00 - Antineoplastic Agents - 316020 56:04 - Antacids and Adsorbents - 379006 Alefacept Aluminum Chloride 84:92 - Skin and Mucous Membrane Agents, 84:12 - Astringents - 307024 92:44 - Immunosuppressive Agents - 303006 Aluminum Hydroxide Alemtuzumab 56:04 - Antacids and Adsorbents - 379007 10:00 - Antineoplastic Agents - 301034 Aluminum Phosphate 92:20 - Immunomodulatory Agents - 315048 56:04 - Antacids and Adsorbents - 379008 10:00 - Antineoplastic Agents - 315048 Alvimopan 92:20 - Immunomodulatory Agents - 301034 56:92 - GI Drugs, Miscellaneous - 308028 Alendronate Amantadine 92:24 - Bone Resorption Inhibitors - 395025 8:18.04 - Adamantanes - 382064 Alfuzosin 28:36.04 - Adamantanes - 382601 12:16.04.12 - Selective alpha-1-Adrenergic Blocking Ambenonium 12:04 - Parasympathomimetic (Cholinergic) Agents - Alglucosidase Alfa 44:00 - Enzymes - 310013 Ambrisentan Alirocumab 48:48 - Vasodilating Agents - 307014 24:06.24 - Proprotein Convertase Subtilisin Kexin Type 24:12.92 - Vasodilating Agents, Miscellaneous - 307014 Amcinonide Aliskiren 84:06.08 - Corticosteroids - 382745 24:32.40 - Renin Inhibitors - 307010 Amifampridine Alitretinoin 92:92 - Other Miscellaneous Therapeutic Agents - 84:92 - Skin and Mucous Membrane Agents, Amifostine 92:56 - Protective Agents - 396014 Allantoin Amikacin 84:28 - Keratolytic Agents - 379004 8:12.02 - Aminoglycosides - 382661 Allogeneic Cultured Keratinocytes and Fibroblasts 8:16.04 - Antituberculosis Agents - 382661 26:04 - Cellular Therapy - 379005 aMILoride Allopurinol 40:28.16 - Potassium-sparing Diuretics - 381046 92:16 - Antigout Agents - 382673 24:08.24.16 - Potassium-sparing Diuretics - 381046 Almotriptan Amino Acid Injections 28:32.28 - Selective Serotonin Agonists - 301039 40:20 - Caloric Agents - 382781 Alogliptin Aminocaproic Acid 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors - 20:28.16 - Hemostatics - 382093 Alosetron Aminoglycosides General Statement 56:36 - Anti-inflammatory Agents - 300011 8:12.02 - Aminoglycosides - 382929 alpha1-Proteinase Inhibitor Aminohippurate 48:92 - Respiratory Tract Agents, Miscellaneous - 36:40 - Kidney Function - 382526 ALPRAZolam Aminolevulinic Acid 28:24.08 - Benzodiazepines - 384001 84:92 - Skin and Mucous Membrane Agents, Alprostadil Aminopenicillins General Statement 24:12.92 - Vasodilating Agents, Miscellaneous - 395022 8:12.16.08 - Aminopenicillins - 385902 Alteplase Aminosalicylic Acid 20:12.20 - Thrombolytic Agents - 389001 8:16.04 - Antituberculosis Agents - 382146 © 2019, American Society of Health-System Pharmacists, Inc. Page 2 of 44 Amiodarone 8:14.16 - Echinocandins - 306014 24:04.04.20 - Class III Antiarrhythmics - 387009 Antacids Amitriptyline 56:04 - Antacids and Adsorbents - 382762 28:16.04.28 - Tricyclics and Other Norepinephrine- 56:28 - Antiulcer Agents and Acid Suppressants - 382762 Anthraquinone Laxatives amLODIPine 56:12 - Cathartics and Laxatives - 382605 24:28.08 - Dihydropyridines - 392044 Anthrax Immune Globulin IV (Human) 24:12.92 - Vasodilating Agents, Miscellaneous - 392044 80:04 - Antitoxins and Immune Globulins - 317015 Ammonia Spirit, Aromatic Anthrax Vaccine Adsorbed 28:20.32 - Respiratory and CNS Stimulants - 382113 80:12 - Vaccines - 301062 Ammonium Chloride Anticonvulsants General Statement 40:04 - Acidifying Agents - 382074 28:12 - Anticonvulsants - 382913 Ammonium Lactate Antihemophilic Factor (Human) 84:28 - Keratolytic Agents - 379010 20:28.16 - Hemostatics - 382075 Amobarbital Antihemophilic Factor (Recombinant) 28:24.04 - Barbiturates - 382418 20:28.16 - Hemostatics - 394027 Amoxapine Antihemophilic Factor (Recombinant), Fc fusion protein 28:16.04.28 - Tricyclics and Other Norepinephrine- 20:28.16 - Hemostatics - 316033 Antihemophilic Factor (Recombinant), GlycoPEGylated- Amoxicillin exei 8:12.16.08 - Aminopenicillins - 385001 20:28.16 - Hemostatics - 379198 56:28 - Antiulcer Agents and Acid Suppressants - 385001 Antihemophilic Factor (Recombinant), PEGylated-aucl Amoxicillin/Clavulanate 20:28.16 - Hemostatics - 318041 8:12.16.08 - Aminopenicillins - 385024 Antihemophilic Factor (Recombinant), Porcine Sequence Amphetamine 20:28.16 - Hemostatics - 316034 28:20.04 - Amphetamines - 382069 Antihistamines General Statement Amphetamines General Statement 4:00 - Antihistamine Drugs - 382920 28:20.04 - Amphetamines - 382902 48:04 - Antihistamines - 382920 Amphotericin B 56:22.08 - Antihistamines - 382920 8:14.28 - Polyenes - 382643 Anti-inhibitor Coagulant Complex Ampicillin 20:28.16 - Hemostatics - 394028 8:12.16.08 - Aminopenicillins - 385002 Antimuscarinics/Antispasmodics General Statement Ampicillin/Sulbactam 12:08.08 - Antimuscarinics/Antispasmodics - 382952 8:12.16.08 - Aminopenicillins - 393021 Antineoplastic Agents General Statement Amsacrine 10:00 - Antineoplastic Agents - 382941 10:00 - Antineoplastic Agents - 379011 92:20 - Immunomodulatory Agents - 382941 Amyl Nitrite Antiretroviral Agents General Statement 24:12.08 - Nitrates and Nitrites - 382344 8:18.08 - Antiretrovirals - 397901 92:12 - Antidotes - 382344 Antithrombin alfa Anagrelide 20:12.04.92 - Anticoagulants, Miscellaneous - 309004 20:12.14 - Platelet-reducing Agents - 308022 Antithrombin III Anakinra 20:12.04.92 - Anticoagulants, Miscellaneous - 308006 92:36 - Disease-modifying Antirheumatic Drugs - Antithymocyte Globulin (Equine) 92:20 - Immunomodulatory Agents - 301072 92:44 - Immunosuppressive Agents - 385025 Anastrozole Antithymocyte Globulin (Rabbit) 68:16.08 - Antiestrogens - 396018 92:44 - Immunosuppressive Agents - 301042 10:00 - Antineoplastic Agents - 396018 Antituberculosis Agents General Statement Angiotensin II 8:16.04 - Antituberculosis Agents - 382908 68:44 - Renin-Angiotensin-Aldosterone System Antivenin (Latrodectus mactans) (Equine) Anidulafungin 80:04 - Antitoxins and Immune Globulins - 382759 © 2019, American Society of Health-System Pharmacists, Inc. Page 3 of 44 92:12 - Antidotes - 382759 10:00 - Antineoplastic Agents - 312023 Antivenin (Micrurus fulvius) (Equine) 44:00 - Enzymes - 312023 80:04 - Antitoxins and Immune Globulins - 386017 Aspartame 92:12 - Antidotes - 386017 40:24 - Salt and Sugar Substitutes - 379013 Apalutamide Aspirin 10:00 - Antineoplastic Agents - 318010 28:08.04.24 - Salicylates - 382878 Apixaban 20:12.18 - Platelet-aggregation Inhibitors - 382878 20:12.04.14 - Direct Factor Xa Inhibitors - 313017 20:12.20 - Thrombolytic
Load more

Recommended publications
  • XTANDI® (Enzalutamide): a Treatment Option for Castration-Resistant Prostate Cancer (CRPC)
    XTANDI® (enzalutamide): A Treatment Option for Castration-Resistant Prostate Cancer (CRPC) XTANDI® (enzalutamide) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with castration-resistant prostate cancer (CRPC).1 XTANDI is the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.1 ABOUT THE ASTELLAS/PFIZER HOW XTANDI WORKS COLLABORATION Astellas and Pfizer jointly XTANDI is indicated for the treatment of CRPC, commercialize XTANDI which is defined as disease progression on in the United States. androgen deprivation therapy (luteinizing hormone-releasing hormone (LHRH) therapy Astellas has responsibility or prior bilateral orchiectomy).2 for manufacturing and all additional regulatory In prostate cancer, the androgen receptor (AR) is a key driver filings globally, as well as of progression.3 XTANDI is an AR inhibitor that is thought commercializing XTANDI to act on multiple steps of the androgen receptor signaling 1 outside the United States. pathway within the tumor cell based on in vitro studies. Select Safety Information Seizure occurred in 0.4% of patients receiving XTANDI in clinical studies. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. Patients in the study had one or more of the following pre-disposing factors: use of medications that may lower the seizure threshold; history of traumatic brain or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection.
    [Show full text]
  • Dimethyl Sulfoxide MSDS
    He a lt h 1 2 Fire 2 2 0 Re a c t iv it y 0 Pe rs o n a l Pro t e c t io n F Material Safety Data Sheet Dimethyl sulfoxide MSDS Section 1: Chemical Product and Company Identification Product Name: Dimethyl sulfoxide Contact Information: Catalog Codes: SLD3139, SLD1015 Sciencelab.com, Inc. 14025 Smith Rd. CAS#: 67-68-5 Houston, Texas 77396 RTECS: PV6210000 US Sales: 1-800-901-7247 International Sales: 1-281-441-4400 TSCA: TSCA 8(b) inventory: Dimethyl sulfoxide Order Online: ScienceLab.com CI#: Not applicable. CHEMTREC (24HR Emergency Telephone), call: Synonym: Methyl Sulfoxide; DMSO 1-800-424-9300 Chemical Name: Dimethyl Sulfoxide International CHEMTREC, call: 1-703-527-3887 Chemical Formula: (CH3)2SO For non-emergency assistance, call: 1-281-441-4400 Section 2: Composition and Information on Ingredients Composition: Name CAS # % by Weight Dimethyl sulfoxide 67-68-5 100 Toxicological Data on Ingredients: Dimethyl sulfoxide: ORAL (LD50): Acute: 14500 mg/kg [Rat]. 7920 mg/kg [Mouse]. DERMAL (LD50): Acute: 40000 mg/kg [Rat]. Section 3: Hazards Identification Potential Acute Health Effects: Slightly hazardous in case of inhalation (lung irritant). Slightly hazardous in case of skin contact (irritant, permeator), of eye contact (irritant), of ingestion, . Potential Chronic Health Effects: Slightly hazardous in case of skin contact (irritant, sensitizer, permeator), of ingestion. CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance may be toxic to blood, kidneys, liver, mucous membranes, skin, eyes.
    [Show full text]
  • AMIFOSTINE for INJECTION Incidence of Grade 2 Or Higher Xerostomia (RTOG Criteria)
    TABLE 4 AMIFOSTINE FOR INJECTION Incidence of Grade 2 or Higher Xerostomia (RTOG criteria) Amifostine for RT p-value only Injection +RT LBL-7062PD Acute DESCRIPTION 51% (75/148) 78% (120/153) p<0.0001 ( 90 days from Amifostine for Injection is an organic thiophosphate cytoprotective agent known chemically ɖ start of radiation) as 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate (ester) and has the following structural formula: Latea 35% (36/103) 57% (63/111) p=0.0016 (9-12 months H2N(CH2)3NH(CH2)2S-PO3H2 post radiation) Amifostine is a white crystalline powder which is freely soluble in water. Its empirical aBased on the number of patients for whom actual data were available. formula is C5H15N2O3PS and it has a molecular weight of 214.22. Amifostine for Injection is the trihydrate form of amifostine and is supplied as a sterile At one year following radiation, whole saliva collection following radiation showed that lyophilized powder requiring reconstitution for intravenous infusion. Each single-use 10 mL more patients given Amifostine for Injection produced >0.1 gm of saliva (72% vs. 49%). vial contains 500 mg of amifostine on the anhydrous basis. In addition, the median saliva production at one year was higher in those patients who CLINICAL PHARMACOLOGY received amifostine (0.26 gm vs. 0.1 gm). Stimulated saliva collections did not show Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a a difference between treatment arms. These improvements in saliva production were pharmacologically active free thiol metabolite. This metabolite is believed to be responsible supported by the patients’ subjective responses to a questionnaire regarding oral dryness.
    [Show full text]
  • The Science of Medicine. the Art of Healing. Going Lecture Free for Genz
    The science of medicine. The art of healing. Going Lecture Free for GenZ Brenda J.B. Roman, M.D. Associate Dean for Medical Education Irina Overman, M.D. Director of Foundations Curriculum Mary Jo Trout, Pharm.D. Director of Therapeutics Curriculum Image obtained from: https://visual.ly/community/infographic/other/generation-z Gen Z Learning Preferences ▪ “Hands on” learning opportunities ▪ Application to “real Life” ▪ Desire community engagement ▪ “Observers” first ▪ Value independent learning ▪ Differs from Millennials (teamwork-oriented approach) ▪ View peers and instructors as valuable resources No attendance problems What we did… Science of Learning Research… What doesn’t work Cognitive illusions ▪ Ineffective strategies that produce massive overconfidence Popular ineffective strategies ▪ Passive repetitive reading ▪ Highlighting and underlining ▪ Summarization ▪ Keyword mnemonics ▪ Imagery for text Science of Learning Research… What does work ▪ Interleaved practice ▪ Elaborative interrogation ▪ Self-explanation ▪ Distributed practice ▪ Practice testing ▪ Retrieval-based learning Foster a Growth Mindset ➢ Willingness to learn ➢ Get comfortable with from reading less than full mastery of material before the session Peer Multiple-Choice Instruction Questions Team-Based WrightQ Learning WrightCurriculum DISTRIBUTED PRACTICE INTERLEAVING READING Peer Instruction Students answer problem sets individually with ARS, then peer instruct and re-answer individually Retrieval-based learning Elaborative interrogation Self-explanation Practice
    [Show full text]
  • Minutes of the CHMP Meeting 14-17 September 2020
    13 January 2021 EMA/CHMP/625456/2020 Corr.1 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 14-17 September 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Addition of the list of participants Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Amifostine Is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery Or Matter-Of-Fact?
    Ha SS, Rubaina K, Lee CS, John V, Seetharamu N. Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact?. J Nephrol Sci.2021;3(1):4-8 Review Article Open Access Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact? Sin Sil Ha1, Kazi Rubaina1, Chung-Shien Lee1,2, Veena John2, Nagashree Seetharamu2* 1St. John’s University, College of Pharmacy and Health Sciences, Department of Clinical Health Professions, 8000 Utopia Parkway, Queens, NY 11439, USA. 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USA. Article Info Abstract Article Notes Despite reports of amifostine possibly protecting nephrotoxicity from Received: December 22, 2020 cisplatin, it has not been recommended by any guidelines committees or Accepted: February 01, 2021 routinely prescribed in clinical practice over the past decade. In this article, *Correspondence: we review literature and guidelines regarding use of amifostine in oncology *Dr. Nagashree Seetharamu, Division of Medical Oncology practice for protection against adverse effects from certain chemotherapeutic and Hematology, Northwell Health Cancer Institute, Donald agents, in particular as a nephro-protectant in patients receiving cisplatin. & Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USA; Email: [email protected]. Background Information ©2021 Seetharamu N. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. Amifostine (Ethyol) is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free Keywords thiol metabolite.
    [Show full text]
  • Conivaptan (Vaprisol )
    January 3, 2007 Conivaptan (Vaprisol ®) DESCRIPTION WHAT YOU MAY NOT BE TOLD Conivaptan (Vaprisol ®) is an inhibitor of arginine Conivaptan is currently approved for euvolemic vasopressin that prevents its binding to V1a and V2 hyponatremia, but the only peer-reviewed published receptors located within the vasculature and renal data is in acute exacerbations of heart failure. It is tubules, respectively. Conivaptan was approved likely that the drug manufacturer will pursue this December 30, 2005, and is a first-in-class agent indication in the future. Conivaptan is also a potent approved for euvolemic hyponatremia. Conivaptan is inhibitor of CYP 3A4 and, as an oral formulation, available in 20 mg/5mL glass ampules. increases the area under the curve of midazolam 2- to 3-fold, simvastatin 3-fold, and amlodipine 2-fold. This WHAT THE PHARMACIST SHOULD KNOW level of interaction is what prevented the oral Euvolemic hyponatremia is most commonly associated formulation from being pursued for FDA approval. with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Causes of this syndrome WHAT THE PATIENT SHOULD KNOW include pulmonary disease (e.g., pneumonia, Conivaptan is used to treat euvolemic hyponatremia, tuberculosis, pleural effusion) and CNS disease (e.g., manifested when a patient has too little sodium in the tumor, subarachnoid hemorrhage, meningitis). SIADH bloodstream but a normal amount of fluid in the body. also occurs with malignancies (e.g., small cell Conivaptan should not be used at this time for heart carcinoma of the lung) and can be caused by drugs failure. Conivaptan has relatively few adverse effects (e.g., chlorpropamide, carbamazepine, narcotic and is well tolerated.
    [Show full text]
  • Synthesis, Characterization and Biological Evaluation of New Potentially Active Hydrazones of Naproxen Hydrazide
    Available online a t www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 2015, 7(10):93-101 (http://derpharmachemica.com/archive.html) ISSN 0975-413X CODEN (USA): PCHHAX Synthesis, characterization and biological evaluation of new potentially active hydrazones of naproxen hydrazide Ali H. Abbas 1, Amer N. Elias 2*and Ammar A. Fadhil 3 1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Tikrit, Salah-Aldin, Iraq 2Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq 3Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq _____________________________________________________________________________________________ ABSTRACT To synthesize new hydrazone derivatives of naproxen with enhanced anti-inflammatory activity and devoid the ulcerogenic side effects. Hydrazones were synthesized by conjugation of naproxen hydrazide with seven natural and synthetic aldehyde and ketone by using glacial acetic acid as catalyst. The synthesis has been carried out following simple methodology in excellent isolated yields.The structure of the synthesized derivatives has been characterized by elemental microanalysis (CHN), FTIR Spectroscopy, and other physicochemical properties.The anti- inflammatory activity of the synthesized compounds was evaluated in vivo using the egg-white induced edema model in rats, and the results of the biological assay was found to be comparable to Naproxen in this regard. The synthesizedhydrazone of
    [Show full text]
  • WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 9/26 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US20 17/024981 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/3 15,400 30 March 2016 (30.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/457,584 10 February 2017 (10.02.2017) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15/473,994 30 March 2017 (30.03.2017) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: AMICUS THERAPEUTICS, INC.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Systematic Review of Tranexamic Acid Adverse Reactions
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Calapai et al., J Pharmacovigilance 2015, 3:4 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000171 Review Open Access Systematic Review of Tranexamic Acid Adverse Reactions Gioacchino Calapai2*, Sebastiano Gangemi1, Carmen Mannucci2, Paola Lucia Minciullo1, Marco Casciaro1, Fabrizio Calapai3, Maria Righi4 and Michele Navarra5 1Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Italy 2Department of Clinical and Experimental Medicine, University of Messina, Italy 3Centro Studi Pharma.Ca, Messina, Italy 4Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Italy 5Department of Drug Sciences and Health Products, University of Messina, Italy *Corresponding author: Gioacchino Calapai, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 5, 98125 Messina, Italy, Tel: +39 090 2213646; Fax: +39 090 221; E-mail: [email protected] Received date: July 06, 2015; Accepted date: July 14, 2015; Published date: July 20, 2015 Copyright: © 2015 Calapai G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background Tranexamic acid is a synthetic lysine derivate that exerts its antifibrinolytic effect by reversible blocking lysine binding sites on plasminogen preventing fibrin degradation. It is widely used for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Aim The aim of our work was to review the literature regarding the best evidence on tranexamic adverse reactions and to describe them according to the apparatus involved.
    [Show full text]